Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Wells Fargo Maintains Overweight on NovoCure, Lowers Price Target to $42

Author: Benzinga Newsdesk | April 03, 2024 12:43pm

Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Overweight and lowers the price target from $49 to $42.

Posted In: NVCR